|
|
|
|
Vol. 60, Issue 5, 1057-1063, November 2001
Molecular Recognition Section, Laboratory of Bioorganic Chemistry,
National Institute of Diabetes and Digestive and Kidney Diseases,
National Institutes of Health, Bethesda, Maryland (Z.-G.G., A.C.,
K.A.J.); Division of Medicinal Chemistry, Leiden/Amsterdam Center for
Drug Research, Leiden University, Leiden, the Netherlands (Z.-G.G.,
J.E.V.M.-K., A.P.I.); and Pharmaceutical Institute, University of Bonn,
Bonn, Germany (C.E.M.)
Allosteric modulators of A1 and A2A adenosine
receptors have been described; however, for the A3
adenosine receptor, neither an allosteric site nor a compound with
allosteric effects has been described. In this study, the allosteric
modulation of human A3 adenosine receptors by a series of
3-(2-pyridinyl)isoquinoline derivatives was investigated by examining
their effects on the dissociation of the agonist radioligand,
[125I]N6-(4-amino-3-iodobenzyl)-5'-N-methylcarboxamidoadenosine
(I-AB-MECA), from the receptor. Several
3-(2-pyridinyl)isoquinoline derivatives, including VUF5455, VUF8502,
VUF8504, and VUF8507, slowed the dissociation of the agonist
radioligand [125I]I-AB-MECA in a concentration-dependent
manner, suggesting an allosteric interaction. These compounds had no
effect on the dissociation of the radiolabeled antagonist
[3H]PSB-11 from the A3 adenosine receptor,
suggesting a selective enhancement of agonist binding. By comparison,
compounds of similar structure (VUF8501, VUF8503, VUF8505), the
classical adenosine receptor antagonist CGS15943 and the A1
receptor allosteric enhancer PD81723 did not significantly influence
the dissociation rate of [125I]I-AB-MECA. The effect of
agonist on forskolin-induced cAMP production was significantly enhanced
by VUF5455. When the subtype-selectivity of the allosteric enhancement
was tested the compounds had no effect on the dissociation of either
[3H]N6-[(R)-phenylisopropyl]adenosine
from the A1 adenosine receptor or
[3H]CGS21680 from the A2A adenosine receptor.
Probing of structure-activity relationships suggested that a carbonyl
group is essential for allosterism but preferred only for competitive
antagonism. The presence of a 7-methyl group decreased the competitive
binding affinity without a major loss of the allosteric enhancing
activity, suggesting that the structural requirements for allosteric
enhancement might be distinct from those for competitive antagonism.
This article has been cited by other articles:
![]() |
Z.-G. Gao, S.-K. Kim, A. S. Gross, A. Chen, J. B. Blaustein, and K. A. Jacobson Identification of Essential Residues Involved in the Allosteric Modulation of the Human A3 Adenosine Receptor Mol. Pharmacol., May 1, 2003; 63(5): 1021 - 1031. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z.-G. Gao, S. G. Kim, K. A. Soltysiak, N. Melman, A. P. IJzerman, and K. A. Jacobson Selective Allosteric Enhancement of Agonist Binding and Function at Human A3 Adenosine Receptors by a Series of Imidazoquinoline Derivatives Mol. Pharmacol., July 1, 2002; 62(1): 81 - 89. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Christopoulos and T. Kenakin G Protein-Coupled Receptor Allosterism and Complexing Pharmacol. Rev., June 1, 2002; 54(2): 323 - 374. [Abstract] [Full Text] [PDF] |
||||